Hengrui Pharmaceutical (600276.SH): HRS-6209 capsules and HRS-4508 tablets approved for clinical trials

Zhitongcaijing · 1d ago

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-6209 capsules and HRS-4508 tablets, and will conduct clinical trials in the near future. Specifically, the safety, tolerability, pharmacokinetics and initial curative effects of HRS-6209 in advanced unresectable or metastatic breast cancer or HRS-9813 in patients with advanced solid tumors is an open, multi-center phase IB/II clinical study.

According to reports, HRS-6209 is a novel selective CDK4 inhibitor that can effectively inhibit cyclin-dependent kinase 4 (CDK4), inhibit downstream Rb phosphorylation, induce tumor cells to block G1 phase, and thereby exert an anti-tumor effect. It is clinically intended to treat advanced malignant solid tumors. Up to now, HRS-6209 related projects have invested about 161 million yuan in R&D (unaudited). HRS-4508 tablets are a novel, efficient, and selective tyrosine kinase inhibitor that exerts an anti-tumor effect by inhibiting tumor cell proliferation. Up to now, the total R&D investment for HRS-4508 film-related projects is about 96.7 million yuan (unaudited).